INVA Innoviva, Inc.
Innoviva, Inc. (INVA) is expected to report earnings on November 4, 2026, after the market close. The consensus earnings estimate is $0.50 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +0.3% since its last earnings release on August 5, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Innoviva, Inc.
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Sector
Healthcare
Industry
Drug Manufacturers / Major